English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/236855
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Therapeutic Efficacy and Biodistribution of Paclitaxel-Bound Amphiphilic Cyclodextrin Nanoparticles: Analyses in 3D Tumor Culture and Tumor-Bearing Animals In Vivo

AuthorsVaran, Gamze; Varan, Cem; Can Öztürk, Süleyman; Benito, Juan M. ; Esendağlı, Güneş; Bilensoy, Erem
KeywordsTumor targeting
Cyclodextrin
Nanoparticle
Paclitaxel
Biodistribution
Breast tumor induced animal model
Issue Date2021
PublisherMultidisciplinary Digital Publishing Institute
CitationNanomaterials 11: 515 (2021)
AbstractThe uniqueness of paclitaxel¿s antimitotic action mechanism has fueled research toward its application in more effective and safer cancer treatments. However, the low water solubility, recrystallization, and side effects hinder the clinical success of classic paclitaxel chemotherapy. The aim of this study was to evaluate the in vivo efficacy and biodistribution of paclitaxel encapsulated in injectable amphiphilic cyclodextrin nanoparticles of different surface charges. It was found that paclitaxel-loaded amphiphilic cyclodextrin nanoparticles showed an antitumoral effect earlier than the drug solution. Moreover, the blank nanoparticles reduced the tumor growth with a similar trend to the paclitaxel solution. At 24 h, the nanoparticles had not accumulated in the heart and lungs according to the biodistribution assessed by in vivo imaging. Therefore, our results indicated that the amphiphilic cyclodextrin nanoparticles are potentially devoid of cardiac toxicity, which limits the clinical use and commercialization of certain polymeric nanoparticles. In conclusion, the amphiphilic cyclodextrin nanoparticles with different surface charge increased the efficiency of paclitaxel in vitro and in vivo. Cyclodextrin nanoparticles could be a good candidate vehicle for intravenous paclitaxel delivery.
Publisher version (URL)http://dx.doi.org/10.3390/nano11020515
URIhttp://hdl.handle.net/10261/236855
Identifiersdoi: 10.3390/nano11020515
issn: 2079-4991
Appears in Collections:(IIQ) Artículos
Files in This Item:
File Description SizeFormat 
827481.pdf4,18 MBUnknownView/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.